Cytogenetic Abnormalities in Patients with Acute Myelogenous Leukemia with Lymphoid Markers

Chang, Yoon Hwan; Lee, Dong Soon; Park, Sung Sup; Kim, Ji Yeon; Park, Myoung Hee; Kim, Byoung Kook; Park, Seonyang; Ahn, Hyo Seop; Shin, Hee Young; Cho, Han Ik

Abstract

BACKGROUND: Immunologic marker studies and cytogenetic studies as well as morphological studies are frequently performed for the differential diagnosis of acute leukemia. We investigated the relationship of between immunophenotyping and cytogenetic abnormalities in acute myelogenous leukemias (AMLs).
METHODS
Total 153 cases of AMLs were included. Morphological, cytochemical, immunophenotypic, and cytogenetic studies were performed. We classified the AML cases according to immunophenotyping and investigated the association between cytogenetic results and immunophenotype. And we compared differences between the AML group with lymphoid markers and that without them.
RESULTS
In 153 cases of AMLs, lymphoid markers (CD2, CD5, CD7, CD19, CD10) were coexpressed in 59 cases (38.6%). Cytogenetic abnormalities were in 106 cases (69.3%). No significant difference in cytogenetic abnormalities was observed between the group with lymphoid markers and without them (76.3% vs. 64.9%, P>0.05). t(8;21)(q22;22) was significantly more frequent in CD19+AMLs (78.3% vs. 7.7%, P<0.0001), compared to CD19-AMLs. In CD2+AMLs, t(15;17)(q24;q21) was significantly more frequent than in CD2-AMLs (81.8% vs. 8.5%, P<0.0001). CD7+AML cases showed fewer cytogenetic abnormalities than AML with other lymphoid markers and various chromosomal abnormalities.
CONCLUSIONS
In AML, cytogenetic abnormalities were different in relation to aberrant lymphoid markers. CD19 vs. t(8;21) and CD2 vs. t(15;17) were closely associated with each other. It is thought that CD7+AML cases are heterogeneous group. We need the study for response to therapy and prognosis in AMLs with lymphoid markers so that the data of this study can be helpful for the diagnosis and treatment.